Gut microbiota reveals whether drug therapies work in inflammatory bowel diseases

January 26, 2021

The prevalence of inflammatory bowel diseases has significantly increased both in Finland and globally. These disorders cannot be entirely cured. Instead, they are treated with anti-inflammatory drugs and, at times, through surgery.

If conventional drug therapies based on anti-inflammatory drugs are ineffective, the diseases can be treated using infliximab, a biological TNF-α blocker that is administered intravenously. Infliximab is an antibody that prevents TNF-α, a pro-inflammatory factor, from binding with inflammatory cells in the intestine. It is effective in reducing inflammation and improving the patient's condition, while also controlling the disease well.

Although infliximab therapy is often effective, roughly 30-40% of patients either do not respond to the treatment or lose response over time. So far, no reliable tests for predicting treatment response are available.

"A test for predicting responses would help to choose drug therapies and avoid unnecessary drug use, which would reduce potential adverse effects and save on drug expenses in the healthcare system," postdoctoral researcher Eija Nissilä says.

In a collaborative project, the University of Helsinki and the Department of Gastroenterology at the Helsinki University Hospital investigated whether any predictors associated with infliximab therapy could be identified in the gut microbiota. The results were published in the Journal of Crohn's and Colitis.

The study revealed that already before treatment the gut microbiota of inflammatory bowel disease patients differed in terms of several bacterial and fungal genera. These differences had a link to infliximab therapy response.

The changes that occurred in the gut microbiota during therapy also differed between patients who presented a response to treatment and those who did not. The gut of non-responsive patients had fewer anti-inflammatory bacteria of the Clostridia family and a higher number of pro-inflammatory bacteria and fungi such as Candida. Certain bacteria found in the intestine predicted a good response to infliximab therapy.

Based on the results, gut bacteria and fungi could potentially be used as indicators when assessing whether to initiate treatment or not.

"Such a predictive test would make it possible to choose the appropriate therapy, providing savings in drug therapy costs in healthcare," Nissilä notes.

University of Helsinki

Related Gut Microbiota Articles from Brightsurf:

Link between Alzheimer's disease and gut microbiota is confirmed
In recent years, the scientific community has suspected that the gut microbiota plays a role in the development of the disease.

Fecal transplantation can restore the gut microbiota of C-section babies
Birth by Cesarean section is detrimental to normal gut microbiota development.

Stronger bones thanks to heat and microbiota
Osteoporosis is characterised by a deterioration of the bones and an increased risk of fractures.

Gut microbiota not involved in the incidence of gestational diabetes mellitus
Consuming the combination of fish oil and probiotic food supplements modulate the composition of gut microbiota in overweight and obese pregnant women, reveals a new study conducted at the University of Turku, Finland.

Studies of gut microbiota and contractility help deal with chronic constipation
Chronic constipation (CC) remains a serious medical and social problem because the complexity of diagnosis, the lack of a single approach to treatment, and unsatisfactory treatment results.

Rely on gut feeling? New research identifies how second brain in gut communicates
You're faced with a big decision so your second brain provides what's normally referred to as 'gut instinct', but how did this sensation reach you before it was too late?

Antioxidant-rich powders from blueberry, persimmon waste could be good for gut microbiota
Feeding the world's growing population in a sustainable way is no easy task.

Gut microbiota provide clues for treating diabetes
The individual mix of microorganisms in the human gastrointestinal tract provides vital clues as to how any future incidence of type 2 diabetes can be predicted, prevented and treated.

Gut Piezo1 regulates gut and bone homeostasis via RNA sensing.
Gut enterochromaffin cells regulate gut and bone homeostasis via serotonin production.

Oat and rye bran fibres alter gut microbiota, reducing weight gain and hepatic inflammation
In a newly published experimental study, the consumption of dietary fibre from oat and rye brans supported the growth of beneficial gut microbiota, which in turn ameliorated cholesterol metabolism, enhanced gut barrier function and reduced hepatic inflammation.

Read More: Gut Microbiota News and Gut Microbiota Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to